Predicted protein targets (top 3)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 20/20 | 0.89 |
| ▸ | TNKS | O95271 | 3/20 | 0.89 |
| ▸ | TNKS2 | Q9H2K2 | 3/20 | 0.89 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30293105 | 1.00 | PARP1 (0.89) | PARP1TNKSTNKS2 | |
| SCHEMBL15204765 | 0.97 | PARP1 (0.85) | PARP1TNKSTNKS2 | |
| SCHEMBL22829810 | 0.94 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL28732598 | 0.93 | PARP1 (0.79) | PARP1TNKSTNKS2 | |
| SCHEMBL22829832 | 0.91 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL22829834 | 0.91 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL15846129 | 0.91 | PARP1 (0.79) | PARP1TNKSTNKS2 | |
| SCHEMBL22829824 | 0.91 | PARP1 (1.00) | PARP1TNKSTNKS2 | |
| SCHEMBL19569971 | 0.90 | PARP1 (0.90) | PARP1TNKSTNKS2 | |
| SCHEMBL22829772 | 0.89 | PARP1 (0.94) | PARP1TNKSTNKS2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 64 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109563080-B | Preparation method of olaparib | 台湾神隆股份有限公司 | 2021-07-30 | — | — | CN | claimed |
| EP-3504196-A1 | PROCESSES FOR PREPARING OLAPARIB | Scinopharm Taiwan, Ltd. (TW) | 2019-07-03 | — | — | EP | claimed |
| WO-2018038680-A1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN, LTD. (TW) | 2018-03-01 | — | — | WO | claimed |
| EP-3504196-B1 | PROCESSES FOR PREPARING OLAPARIB | SCINOPHARM TAIWAN LTD (TW) | 2026-04-08 | — | — | EP | disclosed |
| US-12441757-B2 | Platform for screening NAD+ binding proteins in a cellular context | OREGON HEALTH & SCIENCE UNIVERSITY (US) | 2025-10-14 | — | — | US | disclosed |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | PADARN THERAPEUTICS INC (US) | 2025-08-28 | — | — | US | disclosed |
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2025-08-26 | — | — | US | disclosed |
| CN-115991880-B | Dendrimer PAMAM-G5-TCO and preparation method and application thereof | 中国药科大学 | 2024-03-19 | — | — | CN | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NUVATION BIO INC. (US) | 2023-11-28 | — | — | US | disclosed |
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | UNIV OREGON HEALTH & SCIENCE (US) | 2023-07-06 | — | — | US | disclosed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2009-10-29 | — | — | US | disclosed |
| EP-2064189-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | Kudos Pharmaceuticals Limited (GB) | 2009-06-03 | — | — | EP | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-06-19 | — | — | US | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
| WO-2008047082-A2 | POLYMORPHIC FORM OF 4-[3-(4-CYCLOPROPANECARBONYL-PIPERAZINE-1-CARBONYL)-4-FLUORO-BENZYL]-2H-PHTHALAZIN-1-ONE | KUDOS PHARMACEUTICALS LIMITED (GB) | 2008-04-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12398121-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885TNKS 2187/4885TNKS2 2124/4885 |
| US-20080146575-A1 | 4-[3-(4-cyclopropanecarbonyl-piperazine-1-carbonyl)-4-fluoro-benzyl]-2H-phthalazin-1-one as crystalline; enzyme poly(ADP-ribose)polymerase (synthase)-1 or poly ADP-ribosyltransferase (PARP-1) inhibitor; anticarcinogenic with BRCA2 deficient phenotype; septic shock, ischemic injury, multiple sclerosis | PARP1, PARP11, PARP2 | PARP1 1/4885TNKS 129/4885TNKS2 326/4885 |
| US-12441757-B2 | Platform for screening NAD+ binding proteins in a cellular context | SARM1, PARP16, PARP15 | PARP1 24/4885TNKS 189/4885TNKS2 97/4885 |
| US-20090270617-A1 | PHTHALAZINONE DERIVATIVE | PML, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, NCOA4 | PARP1 379/4885TNKS 2504/4885TNKS2 2719/4885 |
| US-20230212213-A1 | A PLATFORM FOR SCREENING NAD+ BINDING PROTEINS IN A CELLULAR CONTEXT | SARM1, PARP16, NAMPT | PARP1 40/4885TNKS 284/4885TNKS2 146/4885 |
| US-20250270212-A1 | CHIMERIC COMPOUNDS USEFUL IN TREATING DISEASES | WEE1, WEE2, PARP1 | PARP1 3/4885TNKS 48/4885TNKS2 42/4885 |
| US-11826430-B2 | Anti-cancer nuclear hormone receptor-targeting compounds | NCOA1, NCOR1, NCOA3 | PARP1 1873/4885TNKS 2187/4885TNKS2 2124/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.